Christophe Barrea

Dr. Christophe Barrea


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2018 in Neuropediatrics
Verified
Journal Article
Closed access
PDF file
SVSandrine Vaessen
Sandrine Vaessen
SBSaskia Bulk
Saskia Bulk
JHJulie Harvengt
Julie Harvengt
JMJean-Paul Misson
Jean-Paul Misson
CBChristophe Barrea
Christophe Barrea
Neurofibromatosis type 1 (NF1) is a common autosomal dominant disorder with an incidence of ∼1 in 4,000 live births. Neurofibromin, the gene product, is ubiquitously expressed at high levels in the nervous system and functions as a tumor suppressor. Haploinsufficiency of neurofibromin through mutation leads to an increased risk of developing benign and malignant tumors in affected individuals. Although NF1 has complete penetrance, it displays considerable inter- and intrafamilial variability in phenotypic expression which poses disease prediction and management problems. Some NF1 genotype–phenotype correlations have been described. To evaluate the genetic component of variable expressivity in NF1, we examined the phenotypic correlations between affected relatives in 52 NF1 patients from 45 families.

8 July 2024 in International Journal of Hygiene and Environmental Health
Verified
Journal Article
Closed access
CBChristophe Barrea
Christophe Barrea
PDPatrice Dufour
Patrice Dufour
PCPirard Catherine
Pirard Catherine
CCCorinne Charlier
Corinne Charlier
FBFanny Brevers
Fanny Brevers
APAnne-Simone Parent
Anne-Simone Parent

14 January 2021 in Neuropediatrics
Verified
Journal Article
Closed access
PDF file
CBChristophe Barrea
Christophe Barrea
FDFrederique Depierreux
Frederique Depierreux
We report the case of a 7-year-old boy who developed severe recurrent episodes of ataxia. Following the persistence of intrathecal pleocytosis and oligoclonal bands, autoimmune workup was performed, and anti-neurochondrin[1] antibodies in the cerebro-spinal fluid were discovered. Other investigations returned normal, no oncologic accompaniments were found. Clinical examination identified cerebellar ataxia, cervical dystonia, choreic movements of the upper limbs, action tremor, opsoclonus, dysarthria, and akathisis ([video 1]). Cognitive affective cerebellar syndrome, including neuropsychological impairment associated with significant emotional lability, was also found ([Table 1]). Video 1 Walking test showing ataxic gait with deviation, instability especially during the turn around, increase space lift and excessive swinging arms; during the second part, the patient experiences difficulties in fine grasping and intention tremor. Note the presence of cervical dystonia (left laterocollis). Initial corticosteroid therapy (intravenous methylprednisolone 30 mg/kg for 3 days) resulted in significant improvement. However, following the third relapse, a long-term corticotherapy with monthly intravenous methylprednisolone 500 mg/m2 was initiated. After 8 months, to avoid side effects, this treatment was replaced by mycophenolic acid. No relapse was observed since then. The child currently keeps slightly ataxic gait as well as significant cognitive impairment. Autoimmune etiologies of the movement disorders are increasingly recognized, even in children.[2] [3] Unexplained repeated episodes of ataxia of subacute onset may require a workup with comprehensive neural IgG screening, especially since immune therapies seem more effective than what is observed in adults.[4] Received: 02 April 2020 Accepted: 19 April 2020 Publication Date: 14 January 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

23 August 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
FWFranziska Winzig
Franziska Winzig
KKKerstin De Keukeleere
Kerstin De Keukeleere
EBEsther Bartholomeus
Esther Bartholomeus
NDNicolas Deconinck
Nicolas Deconinck
CBChristophe Barrea
Christophe Barrea
TMTrine Mogensen
Trine Mogensen
Varicella zoster virus (VZV) is a neurotropic member of the Herpesviridae family that causes varicella in primary infection and zoster during reactivation but in rare cases can lead to severe neurological complications, such as encephalitis. To identify inborn errors of immunity and unravel pathways involved in VZV central nervous system (CNS) immune responses and pathogenesis, we performed whole exome sequencing on a cohort of 38 children with neurological manifestations, including VZV encephalitis, cerebellitis, or stroke. We identified a total of 46 rare potentially pathogenic variants predicted to be deleterious, including variants in innate antiviral immunity, inflammation, cell stress responses, and autophagy. Collectively, these findings represent a knowledge base for further functional studies, provide new insights into the genetic landscape of VZV CNS infections, and highlight potential genetic defects that may compromise host defense, enabling new avenues for diagnosis and personalized treatment strategies for VZV CNS infections.

27 February 2025 in Molecular Autism
Verified
Journal Article
Open access
PDF file
APAndreea D. Pantiru
Andreea D. Pantiru
SSStijn Van de Sompele
Stijn Van de Sompele
CLClemence Ligneul
Clemence Ligneul
CCCamille Chatelain
Camille Chatelain
CBChristophe Barrea
Christophe Barrea
SCSteven J. Clapcote
Steven J. Clapcote
Background: Intellectual developmental disorder with autism and dysmorphic facies (IDDADF) is a rare syndromic intellectual disability (ID) caused by homozygous disruption of PDZD8 (PDZ domain-containing protein 8), an integral endoplasmic reticulum (ER) protein. All four previously identified IDDADF cases exhibit autistic behavior, with autism spectrum disorder (ASD) diagnosed in three cases. To determine whether autistic behavior is a common outcome of PDZD8 disruption, we studied a third family with biallelic mutation of PDZD8 (family C) and further characterized PDZD8-deficient (Pdzd8 tm1b ) mice that exhibit stereotyped motor behavior relevant to ASD. Methods: Homozygosity mapping, whole-exome sequencing, and cosegregation analysis were used to identify the PDZD8 variant responsible for IDDADF, including diagnoses of ASD, in consanguineous family C. To assess the in vivo effect of PDZD8 disruption on social responses and related phenotypes, behavioral, structural magnetic resonance imaging, and microscopy analyses were conducted on the Pdzd8 tm1b mouse line. Metabolic activity was profiled using sealed metabolic cages. Results: The discovery of a third family with IDDADF caused by biallelic disruption of PDZD8 permitted identification of a core clinical phenotype consisting of developmental delay, ID, autism, and facial dysmorphism. In addition to impairments in social recognition and social odor discrimination, Pdzd8 tm1b mice exhibit increases in locomotor activity (dark phase only) and metabolic rate (both lights-on and dark phases), and decreased plasma triglyceride in males. In the brain, Pdzd8 tm1b mice exhibit increased levels of accessory olfactory bulb volume, primary olfactory cortex volume, dendritic spine density, and ER stress- and mitochondrial fusion-related transcripts, as well as decreased levels of cerebellar nuclei volume and adult neurogenesis. Limitations: The total number of known cases of PDZD8-related IDDADF remains low. Some mouse experiments in the study did not use balanced numbers of males and females. The assessment of ER stress and mitochondrial fusion markers did not extend beyond mRNA levels. Conclusions: Our finding that the Pdzd8 tm1b mouse model and all six known cases of IDDADF exhibit autistic behavior, with ASD diagnosed in five cases, identifies this trait as a common outcome of biallelic disruption of PDZD8 in humans and mice. Other abnormalities exhibited by Pdzd8 tm1b mice suggest that the range of comorbidities associated with PDZD8 deficiency may be wider than presently recognized.

17 March 2025 in Environmental Health
Verified
Journal Article
Open access
PDF file
CBChristophe Barrea
Christophe Barrea
PDPatrice Dufour
Patrice Dufour
PCPirard Catherine
Pirard Catherine
CCCorinne Charlier
Corinne Charlier
FBFanny Brevers
Fanny Brevers
LRLaurence Rousselle
Laurence Rousselle
Children gradually develop motor skills that enable them to move efficiently in various daily activities such as self-care, academics and sports. The impact of prenatal exposure to endocrine disruptors (EDCs) on these performances remains understudied and current results are inconsistent. This study aims at examining the neuromotor function of Belgian preschoolers exposed in utero to a mixture of some of these chemicals. From 2014 to 2016, 66 children (35 boys and 31 girls) were recruited for a longitudinal cohort study. Two polychlorinated biphenyls (PCBs) and four perfluoroalkyl substances (PFASs) were measured in cord serum. A standardized motor evaluation, the Movement Assessment Battery for Children II (MABC-II), and a clinical sensori-motor assessment examining minor neurological dysfunction were administered at 6 years of age. The impact of the mixture of EDCs on neuromotor outcome measures was evaluated using two validated statistical models. Sex-specific analyses were also conducted. Using a principal component analysis, a negative association was identified between a mixture of PCB-153 and − 180 and the Total Clinical examination score in the whole population (β (95% CI) = -15.8 (-26.51; -5.09), p = 0.005). After stratification by sex, negative associations were observed between the Gross Motor score of the MABC-II test and prenatal exposure to a mixture of PFASs and PCB-180, specifically in boys. This association was consistent across both the weighted quantile sum regression model (β (95% CI) = -2.36 (-3.42; -0.62), p = 0.023) and the principal component approach (β (95% CI) = -1.09 (-2.15; -0.13), p = 0.044). Our findings suggest that the neuromotor function of young children is adversely influenced by prenatal exposure to toxicants in a sex-specific manner.